Swiss drugmaker Roche has announced that a new study of their cancer drug Avastin has shown that the drug can significantly slow the progression of brain cancer tumor growth.
Reuters reports that the Phase III AVAglio study was able to successfully extend the survival of people with an aggressive form of brain cancer called glioblastoma, according to Roche, the world’s largest cancer drug manufacturer. In their statement, the Swiss pharmaceutical company stated:
“This study showed that people with glioblastoma, a particularly devastating and aggressive cancer without many treatment options, lived significantly longer without their disease worsening when Avastin was added to radiation and temozolomide chemotherapy.”
The data for the study’s other main endpoint, final overall survival, will be released sometime in 2013, reports Fox News.
Roche also noted that there were no new safety findings in the latest Avastin study, adding that adverse events were the same as those seen in previous trials of the cancer drug across tumor types.
The cancer drug took a hit last year when the US FDA revoked its conditional approval of the drug as a treatment for breast cancer. Since that time, the drug has been overtaken by Roche’s other cancer drugs Rituxan and Herceptin.
Fierce Pharma notes that Avastin generated $2.6 billion in revenue for Roche last year, making it one of the top 10 best selling cancer drugs. Along with the FDA’s dismissal of the drug for breast cancer patients, the US’s cost containment agency turned down the company’s application in July to allow breast cancer patients to take Avastin in conjunction with Xeloda, a chemotherapy treatment.
Check out more information about Avastin and brain tumors below: